Repro-T Company
Arlington, MA Doing business as Portal Biotechnologies
- UEI
- TQ2TYYVLY216
- CAGE
- 9YMC8
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 27 Brunswick Rd, Arlington, MA 02476, USA
- Website
- oracle.com
- Founded
- 1977
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Information Technology
- Software & Services
- Internet Software & Services
- SIC code
- 73 Business Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $349,997 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Advanced Research Projects Agency | $349,997 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| DARPA commercial solutions opening - embedded entrepreneur initiative | Defense Advanced Research Projects Agency | $349,997 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bifrost Biosystems Inc. | Berkeley, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Capra Biosciences Inc. | Sterling, VA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Torchlight Solutions LLC | Arlington, MA | 541330 Engineering Services |
| Armi | Manchester, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Objective Biotechnology, Inc. | Minneapolis, MN | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
Portal Biotechnologies, the biotechnology division of Repro-T Company based in Arlington, Massachusetts, develops high-throughput screening and intracellular delivery platforms for drug discovery and defense applications, operating exclusively as a prime contractor on early-stage federal research and development awards with no set-aside designation.
Portal Biotechnologies holds a $7.879 million multiple-award Other Transaction IDV from the Defense Advanced Research Projects Agency (DARPA), issued June 1, 2025, under the BTO RBC Factory Program, structured outside the FAR regulatory framework under 10 U.S.C. 4022. The vendor received initial task authorization of $1.910 million under CLIN 0001, with subsequent updates to statement of work and technical requirements governing ongoing prototype and production activities. In May 2026, DARPA awarded Portal Biotechnologies a $349,996 definitive firm-fixed-price contract on May 4, 2026, under DARPA's Commercial Solutions Opening program for the Embedded Entrepreneurship Initiative, a twelve-month effort (with optional twenty-four-month Minimum Viable Product phase) tasked to transition and commercialize technologies from prior DARPA R&D programs into military and civilian capabilities. Work is performed in Arlington, Virginia, with ultimate completion scheduled for May 3, 2027.
Portal Biotechnologies is simultaneously advancing its Galaxy system, a mechanoporation-based high-throughput screening platform using disposable cartridges for multiplexed intracellular delivery of biomolecules. The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health awarded the company $1.215 million on September 1, 2026, under CFDA 93.350 to develop this platform for screening impermeable drug molecules and molecular probes in cell-based assays. The project grant runs through August 31, 2028, with performance in Watertown, Massachusetts. The technology addresses early-stage drug discovery bottlenecks by enabling compound screening in live cells before expensive medicinal chemistry campaigns, reducing the risk of pursuing compounds that fail biologically.
Portal Biotechnologies' federal footprint consists of three prime awards with combined potential value of $8.2 million, of which $7.4 million has been obligated. Customer concentration is split between DARPA (two awards, $8.2 million) and NCATS (one award, $1.215 million). Two awards — the CSO Embedded Entrepreneurship contract ($350 thousand) and the NCATS grant ($1.215 million) — reach completion within the next twenty-four months and face recompete exposure. The vendor operates with no subcontract footprint in the visible award portfolio.
Quick answers
Is Repro-T Company registered in SAM.gov?
Yes. Repro-T Company's SAM.gov registration is active through July 7, 2027.
What is Repro-T Company's CAGE code?
Repro-T Company's CAGE code is 9YMC8, and its Unique Entity ID (UEI) is TQ2TYYVLY216.
How much has Repro-T Company received in federal contracts?
Federal contracts obligated $349,997 to Repro-T Company in fiscal years 2023 through 2027.
What is Repro-T Company's most recent federal award?
Repro-T Company's most recent federal grant award is A high throughput platform for intracellular delivery of impermeable drug molecules and molecular probes to enable a… (R44TR006374), from National Center for Advancing Translational Sciences (NIH), on September 1, 2026.
On GovTribe
See Repro-T Company's full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors